ES2619943T3 - Anticuerpos de alta afinidad que neutralizan la enterotoxina B estafilocócica - Google Patents
Anticuerpos de alta afinidad que neutralizan la enterotoxina B estafilocócica Download PDFInfo
- Publication number
- ES2619943T3 ES2619943T3 ES08712978.9T ES08712978T ES2619943T3 ES 2619943 T3 ES2619943 T3 ES 2619943T3 ES 08712978 T ES08712978 T ES 08712978T ES 2619943 T3 ES2619943 T3 ES 2619943T3
- Authority
- ES
- Spain
- Prior art keywords
- amino acid
- acid sequence
- seq
- light chain
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 101000867232 Escherichia coli Heat-stable enterotoxin II Proteins 0.000 title abstract description 3
- 231100000655 enterotoxin Toxicity 0.000 title abstract description 3
- 125000003275 alpha amino acid group Chemical group 0.000 abstract description 30
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 238000010494 dissociation reaction Methods 0.000 abstract 1
- 230000005593 dissociations Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 description 41
- 125000003729 nucleotide group Chemical group 0.000 description 41
- 108020004705 Codon Proteins 0.000 description 20
- 108020004414 DNA Proteins 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 150000007523 nucleic acids Chemical group 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 229960000814 tetanus toxoid Drugs 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 210000000991 chicken egg Anatomy 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Communicable Diseases (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US88327107P | 2007-01-03 | 2007-01-03 | |
| US883271P | 2007-01-03 | ||
| US88840507P | 2007-02-06 | 2007-02-06 | |
| US888405P | 2007-02-06 | ||
| PCT/US2008/000104 WO2008085878A2 (en) | 2007-01-03 | 2008-01-03 | High affinity antibodies that neutralize staphylcoccus enterotoxin b |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2619943T3 true ES2619943T3 (es) | 2017-06-27 |
Family
ID=39529113
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES08712978.9T Active ES2619943T3 (es) | 2007-01-03 | 2008-01-03 | Anticuerpos de alta afinidad que neutralizan la enterotoxina B estafilocócica |
Country Status (9)
| Country | Link |
|---|---|
| US (6) | US8236932B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3138852A1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP5412293B2 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2008205376B2 (cg-RX-API-DMAC7.html) |
| CA (2) | CA2924155C (cg-RX-API-DMAC7.html) |
| DK (1) | DK2109622T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2619943T3 (cg-RX-API-DMAC7.html) |
| PL (1) | PL2109622T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2008085878A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2109622T3 (en) | 2007-01-03 | 2017-02-13 | Morphotek Inc | High affinity antibodies neutralizing staphylococcus enterotoxin B |
| EP2328929A2 (en) * | 2008-09-10 | 2011-06-08 | Bac Ip B.V. | Antigen-binding proteins that inhibit superantigens for the treatment of skin diseases |
| WO2013089877A2 (en) * | 2011-09-27 | 2013-06-20 | Albert Einstein College Of Medicine Of Yeshiva University | Adjuvant therapy for staphylococcal infection with enterotoxin specific mabs |
| SG10201608341XA (en) | 2011-11-23 | 2016-11-29 | Hoffmann La Roche | Cd40l expressing mammalian cells and their use |
| WO2014160121A1 (en) * | 2013-03-14 | 2014-10-02 | Albert Einstein College Of Medicine Of Yeshiva University | Humanized antibodies specific for staphylococcal enterotoxin b |
| EP3532497B1 (en) * | 2016-10-26 | 2024-07-24 | The Board of Trustees of the Leland Stanford Junior University | Modified immunoglobulin hinge regions to reduce hemagglutination |
| BR112019010349A2 (pt) * | 2016-11-23 | 2019-10-08 | Bioverativ Therapeutics Inc | Anticorpos anti-fixa, anti-fxz e antifxa, molécula biespecífica, ácido nulceico, composiçãofarmacêutica e uso dos anteriores |
| KR102124258B1 (ko) * | 2018-10-19 | 2020-06-26 | 대한민국(관리부서 질병관리본부장) | 신속 면역크로마토그래피법을 이용한 황색 포도알균 장독소 b 진단·탐지 키트 및 이를 위한 특이항체와 항체생산세포주 |
| JP7716399B2 (ja) | 2019-11-01 | 2025-07-31 | ブイオーアール バイオファーマ インコーポレーテッド | 抗－ｃｄ４５抗体及びそのコンジュゲート |
| KR102274759B1 (ko) * | 2020-01-16 | 2021-07-09 | 대한민국(질병관리청장) | 황색포도알균 장독소 b에 특이적인 항체 및 이의 용도 |
| CN119101153B (zh) * | 2024-04-30 | 2025-07-08 | 中国人民解放军军事科学院军事医学研究院 | 一种葡萄球菌肠毒素b纳米抗体及其应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2574089A (en) | 1948-06-08 | 1951-11-06 | Cochran Jacqueline | Luggage case having a removable lining |
| US4854432A (en) | 1988-07-06 | 1989-08-08 | American Tourister, Inc. | Suitcase having removable divider with clothing pockets |
| US6713610B1 (en) * | 1990-01-12 | 2004-03-30 | Raju Kucherlapati | Human antibodies derived from immunized xenomice |
| CA2194450A1 (en) | 1994-07-06 | 1996-01-18 | Truckin' Movers Corporation | Convertible carrying case and work platform |
| US6036697A (en) | 1998-07-09 | 2000-03-14 | Scimed Life Systems, Inc. | Balloon catheter with balloon inflation at distal end of balloon |
| CA2345023A1 (en) | 1998-10-07 | 2000-04-13 | The Rockefeller University | Peptides useful for reducing symptoms of toxic shock syndrome and septic shock |
| CA2492671C (en) | 2002-03-22 | 2012-04-17 | Aprogen, Inc. | Humanized antibody and process for preparing same |
| CA2496242A1 (en) | 2002-08-21 | 2004-03-04 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | T-cell epitopes in staphylococcal enterotoxin b |
| EP1661911B8 (en) * | 2003-09-05 | 2013-02-13 | The Chemo-Sero-Therapeutic Research Institute | Protease-resistant modified seb and vaccine containing the same |
| EP1860120B1 (en) * | 2005-02-08 | 2018-01-24 | The Chemo-Sero-Therapeutic Research Institute | Method for improving antibody |
| DK2027155T3 (en) | 2006-06-06 | 2016-05-09 | Crucell Holland Bv | HUMAN BINDING MOLECULES with killer activity against staphylococci and uses thereof |
| DK2109622T3 (en) * | 2007-01-03 | 2017-02-13 | Morphotek Inc | High affinity antibodies neutralizing staphylococcus enterotoxin B |
-
2008
- 2008-01-03 DK DK08712978.9T patent/DK2109622T3/en active
- 2008-01-03 CA CA2924155A patent/CA2924155C/en active Active
- 2008-01-03 JP JP2009544928A patent/JP5412293B2/ja active Active
- 2008-01-03 WO PCT/US2008/000104 patent/WO2008085878A2/en not_active Ceased
- 2008-01-03 US US11/969,097 patent/US8236932B2/en active Active
- 2008-01-03 ES ES08712978.9T patent/ES2619943T3/es active Active
- 2008-01-03 EP EP16192106.9A patent/EP3138852A1/en not_active Withdrawn
- 2008-01-03 AU AU2008205376A patent/AU2008205376B2/en active Active
- 2008-01-03 EP EP08712978.9A patent/EP2109622B1/en active Active
- 2008-01-03 CA CA2674382A patent/CA2674382C/en active Active
- 2008-01-03 PL PL08712978T patent/PL2109622T3/pl unknown
-
2012
- 2012-07-02 US US13/540,330 patent/US8889846B2/en active Active
-
2013
- 2013-06-14 JP JP2013126119A patent/JP5881646B2/ja active Active
- 2013-07-16 US US13/943,060 patent/US8895704B2/en active Active
-
2014
- 2014-10-15 US US14/515,146 patent/US9359428B2/en active Active
-
2016
- 2016-02-02 JP JP2016017809A patent/JP6195946B2/ja active Active
- 2016-05-02 US US15/144,334 patent/US9868780B2/en active Active
-
2017
- 2017-12-12 US US15/839,403 patent/US10364284B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| DK2109622T3 (en) | 2017-02-13 |
| US20140072553A1 (en) | 2014-03-13 |
| AU2008205376A1 (en) | 2008-07-17 |
| PL2109622T3 (pl) | 2017-06-30 |
| US20180094048A1 (en) | 2018-04-05 |
| JP5412293B2 (ja) | 2014-02-12 |
| US8895704B2 (en) | 2014-11-25 |
| US20130183314A1 (en) | 2013-07-18 |
| JP2013216673A (ja) | 2013-10-24 |
| JP5881646B2 (ja) | 2016-03-09 |
| US9359428B2 (en) | 2016-06-07 |
| CA2674382A1 (en) | 2008-07-17 |
| US8889846B2 (en) | 2014-11-18 |
| WO2008085878A2 (en) | 2008-07-17 |
| US10364284B2 (en) | 2019-07-30 |
| JP2010514459A (ja) | 2010-05-06 |
| EP2109622B1 (en) | 2016-11-09 |
| US20150050276A1 (en) | 2015-02-19 |
| CA2674382C (en) | 2016-05-31 |
| JP2016146824A (ja) | 2016-08-18 |
| US20120171223A1 (en) | 2012-07-05 |
| WO2008085878A3 (en) | 2009-02-26 |
| AU2008205376B2 (en) | 2012-07-12 |
| EP2109622A2 (en) | 2009-10-21 |
| CA2924155A1 (en) | 2008-07-17 |
| US9868780B2 (en) | 2018-01-16 |
| EP3138852A1 (en) | 2017-03-08 |
| JP6195946B2 (ja) | 2017-09-13 |
| US8236932B2 (en) | 2012-08-07 |
| US20170121396A1 (en) | 2017-05-04 |
| CA2924155C (en) | 2020-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2619943T3 (es) | Anticuerpos de alta afinidad que neutralizan la enterotoxina B estafilocócica | |
| Cheung et al. | A proteomics approach for the identification and cloning of monoclonal antibodies from serum | |
| Sawant et al. | Toward drug-like multispecific antibodies by design | |
| Kovaltsuk et al. | How B-cell receptor repertoire sequencing can be enriched with structural antibody data | |
| Xiang et al. | Integrative proteomics identifies thousands of distinct, multi-epitope, and high-affinity nanobodies | |
| Cao et al. | B. 1.1. 529 escapes the majority of SARS-CoV-2 neutralizing antibodies of diverse epitopes | |
| Van de Bovenkamp et al. | Variable domain N-linked glycans acquired during antigen-specific immune responses can contribute to immunoglobulin G antibody stability | |
| US20220415436A1 (en) | Computer assisted antibody re-epitoping | |
| Cho et al. | Shared VH1-46 gene usage by pemphigus vulgaris autoantibodies indicates common humoral immune responses among patients | |
| CA3116289A1 (en) | Trem2 stabilizing antibodies | |
| EP4442706A2 (en) | Canine antibody libraries | |
| IL273196B2 (en) | Claudin6 antibodies and methods of treating cancer | |
| HRP20192218T1 (hr) | Humanizirani miševi koji izražavaju teške lance koji sadrže vl domene | |
| BRPI0511782A (pt) | anticorpos anti-cd3 e métodos de uso dos mesmos | |
| BR112015004783B1 (pt) | Anticorpo isolado totalmente humano, humanizado ou quimérico, que se liga especificamente a il-18, mas não se liga ao complexo il-18/proteína de ligação a il18, seu método de produção e seu uso, polinucleotídeo isolado, vetor de clonagem ou expressão, microrganismos transgênicos e seu método de produção, e composição farmacêutica e seu uso | |
| BRPI0610796B8 (pt) | anticorpo humano ou humanizado isolado, ou um fragmento fab ou scfv do mesmo, sequência de ácidos nucleicos, vetor, e, uso de um anticorpo | |
| AR053514A1 (es) | Anticuerpos dirigidos contra cd20 y sus usos | |
| Zielonka et al. | The shark strikes twice: hypervariable loop 2 of shark IgNAR antibody variable domains and its potential to function as an autonomous paratope | |
| JP2023106414A (ja) | 真核宿主細胞において多量体タンパク質を産生する方法 | |
| Lee et al. | A two-in-one antibody engineered from a humanized interleukin 4 antibody through mutation in heavy chain complementarity-determining regions | |
| Hollingsworth et al. | Discovery and multimerization of cross-reactive single-domain antibodies against SARS-like viruses to enhance potency and address emerging SARS-CoV-2 variants | |
| Fernández-Quintero et al. | Comparing antibody interfaces to inform rational design of new antibody formats | |
| Raybould et al. | Contextualising the developability risk of antibodies with lambda light chains using enhanced therapeutic antibody profiling | |
| Reyes et al. | Broadly inhibitory antibodies against severe malaria virulence proteins | |
| US20250147036A1 (en) | Methods for identification of antigen-binding molecules |